ASH 2022 | Genomic testing in CLL & uptake in community practices
Nilanjan Ghosh, MD, PhD, Levine Cancer Institute, Charlotte, NC, briefly discusses the results of a study evaluating the uptake of genomic testing for chronic lymphocytic leukemia (CLL) in small centers, describing the different tests available, when they should be performed, and how they may impact treatment decisions. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
Explore our dedicated feature on genomic testing in CLL here: http://bit.ly/403y417
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Genmab: Consultancy; Loxo Oncology: Consultancy; Novartis: Consultancy; Roche/Genentech: Consultancy, Research Funding; Karyopharm: Consultancy; Incyte: Consultancy; Beigene: Consultancy; Gilead: Consultancy, Research Funding, Speakers Bureau; Bristol Myers Squibb: Consultancy, Research Funding, Speakers Bureau; Janssen: Consultancy, Speakers Bureau; Pharmacyclics: Consultancy, Speakers Bureau; AstraZeneca: Consultancy, Speakers Bureau; TG Therapeautics: Consultancy, Research Funding; Seagen: Consultancy; Levine Cancer Institute: Current Employment, Honoraria, Research Funding; Adaptive Biotech: Consultancy; ADC Therapeautics: Consultancy; Epizyme: Speakers Bureau; Morphosys: Research Funding; AbbVie: Research Funding.
